Permanens Capital L.P. bought a new stake in United Therapeutics Co. (NASDAQ:UTHR) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 6,000 shares of the biotechnology company’s stock, valued at approximately $704,000. United Therapeutics makes up approximately 0.2% of Permanens Capital L.P.’s holdings, making the stock its 24th largest holding.
A number of other institutional investors have also recently modified their holdings of UTHR. Captrust Financial Advisors lifted its stake in United Therapeutics by 384.9% in the fourth quarter. Captrust Financial Advisors now owns 257 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 204 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its position in shares of United Therapeutics by 10,537.5% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 3,551,229 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 3,517,845 shares in the last quarter. First Mercantile Trust Co. lifted its position in shares of United Therapeutics by 47.8% during the fourth quarter. First Mercantile Trust Co. now owns 340 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 110 shares in the last quarter. Financial Gravity Companies Inc. purchased a new stake in shares of United Therapeutics during the fourth quarter worth $44,000. Finally, Financial Gravity Wealth Inc. purchased a new stake in shares of United Therapeutics during the first quarter worth $46,000. 96.32% of the stock is owned by institutional investors and hedge funds.
In other United Therapeutics news, Director Raymond Dwek sold 3,750 shares of the firm’s stock in a transaction dated Thursday, June 27th. The shares were sold at an average price of $76.11, for a total value of $285,412.50. Following the completion of the sale, the director now directly owns 3,750 shares in the company, valued at $285,412.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Richard Giltner sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $79.05, for a total transaction of $395,250.00. Following the transaction, the director now directly owns 5,000 shares of the company’s stock, valued at approximately $395,250. The disclosure for this sale can be found here. Corporate insiders own 8.20% of the company’s stock.
Shares of NASDAQ:UTHR traded up $1.05 on Friday, reaching $78.06. 676,606 shares of the company traded hands, compared to its average volume of 855,804. The business has a 50-day simple moving average of $84.12. United Therapeutics Co. has a 52 week low of $75.72 and a 52 week high of $130.00. The stock has a market capitalization of $3.37 billion, a PE ratio of 5.83 and a beta of 1.15. The company has a debt-to-equity ratio of 0.45, a current ratio of 7.19 and a quick ratio of 6.84.
United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported ($11.32) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $2.64 by ($13.96). The company had revenue of $362.70 million for the quarter, compared to the consensus estimate of $335.72 million. United Therapeutics had a negative net margin of 9.36% and a negative return on equity of 5.78%. The firm’s quarterly revenue was down 6.8% compared to the same quarter last year. During the same period last year, the business posted $3.76 earnings per share. On average, analysts expect that United Therapeutics Co. will post -5.03 earnings per share for the current fiscal year.
United Therapeutics Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
Featured Story: What is total return in investing?
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.